Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash & Equivalents: 2014-2025

Historic Cash & Equivalents for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $169.6 million.

  • Viridian Therapeutics, Inc.\DE's Cash & Equivalents fell 15.31% to $169.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.6 million, marking a year-over-year decrease of 15.31%. This contributed to the annual value of $99.6 million for FY2024, which is 3.14% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Cash & Equivalents stood at $169.6 million for Q3 2025, which was up 44.60% from $117.3 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Cash & Equivalents' 5-year high stood at $344.2 million during Q3 2022, with a 5-year trough of $27.7 million in Q2 2021.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Cash & Equivalents averaged around $117.5 million, with its median value being $107.7 million (2024).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Cash & Equivalents soared by 361.70% in 2021, and later plummeted by 67.58% in 2023.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Cash & Equivalents stood at $42.3 million in 2021, then spiked by 267.81% to $155.6 million in 2022, then crashed by 33.91% to $102.8 million in 2023, then fell by 3.14% to $99.6 million in 2024, then fell by 15.31% to $169.6 million in 2025.
  • Its Cash & Equivalents stands at $169.6 million for Q3 2025, versus $117.3 million for Q2 2025 and $116.2 million for Q1 2025.